Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an antiepileptic presented as an oral tablet for oral use. It is indicated for the treatment of various seizure types in patients with epilepsy. GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Levetiracetam is an antiepileptic drug used to control seizures across several epilepsy syndromes.

- Partial onset seizures: reduces the frequency of focal seizures with or without secondary generalisation. - Generalized tonic‑clonic seizures: helps prevent the occurrence of convulsive seizures. - Myoclonic seizures: diminishes rapid, involuntary muscle jerks associated with myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Fatigue: feeling unusually tired or low in energy. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Mood disorders: depression, suicidal thoughts, or aggressive behaviour. - Hematologic abnormalities: low blood cell counts such as neutropenia or thrombocytopenia.

Before initiating therapy, several safety considerations should be reviewed.

- Renal function: assess and adjust dose in patients with impaired renal clearance. - Pregnancy: discuss potential risks with a healthcare professional, as safety data are limited. - Breastfeeding: evaluate benefits versus potential exposure to the infant. - Driving and operating machinery: caution due to possible dizziness or drowsiness. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety.

Major Interactions (Avoid): - Carbamazepine: may lower levetiracetam plasma concentrations. - Phenobarbital: can reduce levetiracetam levels, diminishing seizure control. - Phenytoin: may decrease levetiracetam exposure, requiring monitoring.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation or drowsiness. - Alcohol: can increase central nervous system effects, leading to heightened dizziness or impairment.